Drug Hunter Secures Seed Investment Led by Teamworthy Ventures to Expand Drug Discovery Knowledge Platform

BOSTON and NASHVILLE, Tenn. and NEW YORK, Sept. 15, 2025 /PRNewswire/ -- Drug Hunter, the trusted knowledge platform for drug discovery R&D teams, today announced a Seed investment led by Teamworthy Ventures. The funding will accelerate Drug Hunter's mission to empower scientists and R&D leaders with the insights they need to confidently discover tomorrow's medicines.

Drug Hunter is already relied upon by researchers at over 200 leading organizations investing in pharmaceutical R&D, including Eli Lilly, Biogen, Merck KGaA, Isomorphic Labs, Deerfield Management, and the National Institutes of Health (NIH). Drug Hunter offers unparalleled, searchable insights from scientific literature, patents, and early disclosures distilled by an expert team of industry scientists.

Industry leaders describe Drug Hunter as an indispensable tool for accelerating decision-making, surfacing novel ideas, and avoiding costly mistakes:

"Drug Hunter complements our approach at Isomorphic Labs, providing trusted, high-quality drug discovery insights that allow our team to rapidly integrate the latest findings into our hypothesis-driven drug design. Drug Hunter's expertly curated data and insights offer crucial real-world precedent and competitive context, empowering our teams to make better-informed decisions where it matters most." – Rebecca Paul, Director of Medicinal Drug Design at Isomorphic Labs

"Drug Hunter distills the core knowledge of our field and makes it accessible, while also serving as a hub that brings the medicinal chemistry community together. It has become an organizing force that connects scientists across companies and celebrates the impact of our work." - Chris Helal, Head of Synthetic Medicine Design, Biogen

"Few resources combine scientific rigor with day-to-day utility the way Drug Hunter does. From drug targets to design principles and enabling technologies, it's become essential across discovery programs." - Ken Brameld, Head of Discovery at Alumis

"Drug Hunter is like having your smartest colleagues read every journal, patent, and conference abstract for you, then just tell you the key insights that actually matter." -Wendy Young, Scientific Advisor, Board Member, former SVP Small Molecule Drug Discovery, Genentech.

"Drug Hunter has rapidly developed into the premier resource for the medicinal chemistry and drug discovery community, providing detailed in-depth profiles of prominent contemporary compounds, thorough analyses of drug targets and mechanistic approaches and offering key insight into strategies and tactics for solving the kinds of problems encountered by all molecular architects." - Nicholas Meanwell, Distinguished Professor, The Baruch S. Blumberg Institute, Adjunct Professor, The University of Michigan and Rutgers University.

"Drug Hunter is full of experienced, insightful people who know exactly what's useful to drug discovery scientists." – Benjamin Taft, Senior Director of Medicinal Chemistry, IDEAYA Biosciences

"It's the kind of resource I wish had existed earlier in my career—and one I now recommend to everyone in the field." – Mark Murcko, Founding CSO, Relay Therapeutics & Dewpoint Therapeutics

Thomas Lehrman, Managing Partner of Teamworthy Ventures, says, "Our team has been fortunate to partner with several leading life sciences R&D software and technology-enabled services companies, including Uncountable, Academia.edu, and Quartzy. We are thrilled to partner with Founder and CEO Dennis Hu and his entire talented team in their important mission to help drug discovery scientists develop new life-changing medicines faster. Our many conversations with customers revealed that Drug Hunter is a mission-critical information service accelerating R&D efforts among some of our most sophisticated life sciences research institutions."

Looking ahead, the company plans to enhance its capabilities with expanded scientific coverage of technologies, modalities, and therapeutic areas, enriched chemical structure databases, enhanced search and analytics tools that make it even easier for teams to extract insights that matter, and a mobile application that immediately highlights disclosures to scientists.

"We are excited to partner with Teamworthy Ventures and join the outstanding teams in their portfolio to serve the extraordinary community of scientists who inspire us daily," said Dennis Hu, Founder & CEO of Drug Hunter. "Their deep experience in research and information services, as well as in healthcare and life sciences, made them an ideal partner for our team to expand our team and capabilities to meet the needs of a rapidly evolving industry."

About Drug Hunter

Drug Hunter is the essential knowledge platform for R&D organizations turning molecules into medicines. Drug Hunter's experts keep you current by connecting the dots, distilling industry lessons from thousands of sources into a one-of-a-kind searchable platform for drug discovery knowledge you can apply to make better decisions and solve critical discovery challenges. Founded and operated by a team of industry scientists, over 200 leading biotech and pharma R&D organizations rely on Drug Hunter to stay ahead of the curve.

Website: www.drughunter.com

About Teamworthy Ventures

Teamworthy Ventures is a mission-driven venture investment firm with offices in New York City and Nashville. Our mission is to partner with outstanding entrepreneurial teams to build companies of purpose, integrity, and enduring value. Since our founding in 2015, select portfolio companies include: Toast, OpenGov, Ibotta, SeatGeek, Teamworks, Uncountable, Carta, G2, Slice, Hallow, Shift5, Vetcove, Vestwell, Virtru, Academia.edu, and more. The Teamworthy Ventures Founder Fellowship supports pre-seed and seed stage founders and is currently accepting applications for Spring 2026.

Website: www.teamworthy.com

SOURCE Drug Hunter